Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imunon, Inc. is conducting a Phase 3 clinical trial titled A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer. The study aims to assess the safety and effectiveness of IMNN-001 combined with standard chemotherapy in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. This trial is significant as it explores potential advancements in treatment options for these aggressive cancers.
The intervention being tested is IMNN-001, an IL-12 plasmid formulated with PEG-PEI-Cholesterol Lipopolymer, administered intraperitoneally. It is combined with standard chemotherapy drugs such as Paclitaxel and Carboplatin, aiming to enhance treatment efficacy.
This interventional study employs a randomized, parallel assignment model with no masking. Its primary purpose is treatment, comparing the experimental arm of IMNN-001 plus standard chemotherapy against a control arm receiving only standard chemotherapy.
The trial began on July 9, 2025, with recruitment currently ongoing. The last update was submitted on August 8, 2025. These dates are crucial as they indicate the trial’s progression and current status.
The market implications of this study could be significant for Imunon, Inc., as positive results may enhance their stock performance and attract investor interest. This trial places Imunon in a competitive position within the oncology sector, potentially impacting industry dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.